Market Size of Tourette Syndrome Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 10.40 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Tourette Syndrome Treatment Market Analysis
The tourette syndrome (TS) treatment market is expected to register a CAGR of 10.4% over the forecast period.
The outbreak of the COVID-19 pandemic led to worsening symptoms, including tics, hyperactivity, rage attacks, obsessions/compulsions, and anxiety amongst virus-affected people, which increased demand for Tourette syndrome treatment drugs. For instance, according to the research study published by the eClinicalMedicine Journal in February 2023, the incidence of tics in young people and children surged across all age and sex groups during the initial phase of the pandemic. As per the same source, the incidence of mental health disorders such as anxiety also increased amongst those suffering from tic symptoms. Hence, the rising incidence of tics symptoms during the initial phase of the pandemic led to an increased demand for medications, therapies, and other treatments for Tourette syndrome. However, with the decrease in COVID-19 cases worldwide, the incidence of tics is also controlled, and the market is expected to register stable growth during the forecast period.
The major factors driving the growth of the market are the increasing cases of Tourette syndrome across the globe and the rising focus on Tourette syndrome research. In addition, increasing research work and studies on Tourette syndrome to investigate underlying causes and treatment efficacy across the globe are also anticipated to propel market growth. For instance, according to the data released by ClinicalTrials.gov in March 2023, Tourette syndrome (TS) and chronic tic disorder (CTD) affect approximately 1% of 5-18-year-olds globally. In addition, according to the data released by the ADHD Foundation in March 2022, globally, approximately 1 out of 100 school-aged children have diagnosable TS. As per the same source, more than 300,000 children and adults are living with TS in the United Kingdom. Furthermore, around 85% of people with TS suffer from various neurological diseases such as Attention Deficit Hyperactivity Disorder (ADHD), Obsessive Compulsive Disorder (OCD), and Anxiety. Moreover, the rising number of clinical trials related to TS is also projected to drive market growth during the forecast period. For instance, in November 2022, Emalex Biosciences closed a Series D funding of around USD 250 million for its phase III trial of ecopipam drug for Tourette syndrome.
Therefore, the high prevalence of TS all over the world and the rising number of clinical trials are projected to drive market growth during the forecast period. However, a lack of awareness about Tourette syndrome in developing regions is likely to impede the market's growth over the forecast period.
Tourette Syndrome Treatment Industry Segmentation
As per the scope of the report, Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Tourette syndrome is associated with other additional neurobehavioral problems such as inattention, impulsivity (attention deficit hyperactivity disorder-ADHD), problems with reading and writing, and obsessive-compulsive symptoms. The Tourette syndrome treatment market is segmented by product (antipsychotics and non-antipsychotics) and geography (North America, Europe, Asia-Pacific, and rest of the world). The report offers the value (in USD) for the above segments.
| By Product | |
| Antipsychotics | |
| Non Antipsychotics |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| Rest of the World |
Tourette Syndrome Treatment Market Size Summary
The Tourette Syndrome treatment market is poised for significant growth, driven by an increasing prevalence of the condition and heightened research efforts globally. The COVID-19 pandemic exacerbated symptoms such as tics and anxiety, leading to a surge in demand for treatments. This demand is supported by ongoing research into the underlying causes and treatment efficacy of Tourette Syndrome, with a notable focus on antipsychotic drugs, which have shown substantial effectiveness in reducing tic severity. The market is characterized by a competitive landscape, with major players like AstraZeneca and Teva Pharmaceutical Industries actively participating in research and development to enhance treatment options.
North America is expected to hold a substantial share of the market, fueled by a high prevalence of Tourette Syndrome and robust research initiatives in the region. The presence of key market players, along with public and private awareness campaigns, further propels market growth. The market's expansion is also supported by the increasing number of clinical trials aimed at testing new treatments and the ongoing development of innovative therapeutic devices. Despite challenges such as limited awareness in developing regions, the market is anticipated to experience steady growth, driven by the high efficacy of existing treatments and the continuous pursuit of new therapeutic solutions.
Tourette Syndrome Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Cases of Tourette Syndrome
-
1.2.2 Rising Focus on Tourette Syndrome Research
-
-
1.3 Market Restraints
-
1.3.1 Lack of Awareness in Developing Region
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Product
-
2.1.1 Antipsychotics
-
2.1.2 Non Antipsychotics
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Rest of the World
-
-
Tourette Syndrome Treatment Market Size FAQs
What is the current Global Tourette Syndrome Treatment Market size?
The Global Tourette Syndrome Treatment Market is projected to register a CAGR of 10.40% during the forecast period (2024-2029)
Who are the key players in Global Tourette Syndrome Treatment Market?
AstraZeneca Plc, Viatris Inc. (Mylan Inc.), Otsuka Pharmaceutical Co., Ltd., Reviva Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. (Auspex Pharmaceuticals, Inc.) are the major companies operating in the Global Tourette Syndrome Treatment Market.
